Skip to content
Stocks News
Enter Ticker Symbol
  • Home
  • FEATURED COMPANY
  • ANALYST COVERAGE
  • NEWS
  • SUBSCRIBE
  • CONTACT

ANALYST COVERAGE

coreweave-stock-(crwv)-scores-citizens-jmp-upgrade,-raymond-james-assigns-buy-rating

CoreWeave Stock (CRWV) Scores Citizens JMP Upgrade, Raymond James Assigns Buy Rating

Sep 18, 2025

Artificial intelligence (AI) infrastructure firm CoreWeave (CRWV) scored a rating upgrade from Citizens JMP, while a top Raymond…

Read more
soundhound-ai-(soun):-how-fresh-analyst-coverage-and-financial-probe-are-shaping-valuation-expectations

SoundHound AI (SOUN): How Fresh Analyst Coverage and Financial Probe Are Shaping Valuation Expectations

Sep 17, 2025

If you have been following SoundHound AI (SOUN) lately, you have probably noticed the stock is at the…

Read more
canadian-analyst-coverage-update:-sept-16th,-2025

Canadian Analyst Coverage Update: Sept 16th, 2025

Sep 17, 2025

Analyst Ratings (Canada) The following are today’s latest 33 analyst ratings tracked from muliple analysts for Canadian listed…

Read more
trevi-therapeutics-(trvi):-assessing-valuation-as-analyst-coverage-highlights-haduvio’s-potential-in-chronic-cough-market

Trevi Therapeutics (TRVI): Assessing Valuation as Analyst Coverage Highlights Haduvio’s Potential in Chronic Cough Market

Sep 17, 2025

What’s Behind the Buzz With Trevi Therapeutics? Trevi Therapeutics (TRVI) is in the spotlight this week after Morgan…

Read more
canadian-analyst-coverage-update:-sept-17th,-2025

Canadian Analyst Coverage Update: Sept 17th, 2025

Sep 17, 2025

Analyst Update (Canada) Adentra Inc. (ADEN:CA) had its Outperform rating maintained by CIBC with a target price of…

Read more
analyst-barclays-initiates-coverage-on-c4-therapeutics-(cccc)-with-overweight-rating

Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) with Overweight Rating

Sep 17, 2025

Key Takeaways Barclays initiates coverage on C4 Therapeutics (CCCC) with an ‘Overweight’ rating. Current price target set at…

Read more
biohaven-(bhvn)-shares-surge-following-positive-analyst-coverage

Biohaven (BHVN) Shares Surge Following Positive Analyst Coverage

Sep 17, 2025

Biohaven (BHVN) garners a “Buy” rating from Citi, with a target price of $28, amid expectations for troriluzole…

Read more
this-protagonist-therapeutics-analyst-begins-coverage-on-a-bullish-note;-here-are-top-5-initiations-for-wednesday-–-biohaven-(nyse:bhvn),-avient-(nyse:avnt)

This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday – Biohaven (NYSE:BHVN), Avient (NYSE:AVNT)

Sep 17, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst…

Read more
canadian-analyst-coverage-update:-sept-16th,-2025

Canadian Analyst Coverage Update: Sept 16th, 2025

Sep 17, 2025

Analyst Ratings (Canada) The following are today’s latest 33 analyst ratings tracked from muliple analysts for Canadian listed…

Read more
canadian-analyst-coverage-update:-sept-16th,-2025

Canadian Analyst Coverage Update: Sept 16th, 2025

Sep 17, 2025

Analyst Ratings (Canada) The following are today’s latest 33 analyst ratings tracked from muliple analysts for Canadian listed…

Read more
firefly-aerospace-earnings-are-imminent;-these-most-accurate-analysts-revise-forecasts-ahead-of-earnings-call

Firefly Aerospace Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Sep 17, 2025

Firefly Aerospace Inc. FLY will release earnings results for the second quarter after the closing bell on Monday,…

Read more
canadian-analyst-coverage-update:-sept-16th,-2025

Canadian Analyst Coverage Update: Sept 16th, 2025

Sep 17, 2025

Analyst Ratings (Canada) The following are today’s latest 33 analyst ratings tracked from muliple analysts for Canadian listed…

Read more
  1. Pages:
  2. «
  3. 1
  4. ...
  5. 220
  6. 221
  7. 222
  8. 223
  9. 224
  10. 225
  11. 226
  12. ...
  13. 468
  14. »

Posts pagination

Newer posts Page 1 … Page 223 … Page 468 Older posts

The content presented on this site is intended solely for entertainment purposes and should not be construed as an invitation to engage in the purchase or sale of securities. Each content provider featured on 10x Wealth Report brings a unique perspective and predisposition, which may not necessarily align with that of 10x Wealth Report. It is crucial to recognize that 10x Wealth Report is not a registered financial advisor or firm. Read More full disclaimer

CATEGORIES

  • FEATURED COMPANY
  • NEWS
  • ANALYST COVERAGE
  • Special Post
  • CONTACT
  • SUBSCRIBE
  • Privacy Policy
  • Terms or Service
  • Disclaimer

CONNECT & FOLLOW

© 10x Wealth Report Copyright 2024.